Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents

Arterioscler Thromb Vasc Biol. 2007 Feb;27(2):400-6. doi: 10.1161/01.ATV.0000254677.12861.b8. Epub 2006 Dec 7.

Abstract

Objective: Drug eluting stents (DES) reduce the incidence of restenosis after coronary angioplasty. Enthusiasm has been tempered by a possible increased risk of in-stent thrombosis. We examined the effects of paclitaxel and rapamycin on the endothelial transcriptome to identify alterations in gene expression associated with thrombosis.

Methods and results: Gene expression profiling was performed on human coronary artery endothelial cells treated with rapamycin or paclitaxel. Plasminogen activator inhibitor-1 (PAI-1) was the most consistently induced transcript in rapamycin-treated human coronary artery endothelial cells. RT-PCR and ELISA were performed to confirm positive findings. Transgenic mice engineered to express enhanced green fluorescent protein under control of the human PAI-1 promoter were also treated. Rapamycin and paclitaxel treated endothelial cells produced dose-dependent increases in PAI-1. There was a variable effect on endothelial tissue-type plasminogen activator (t-PA) expression. Enhanced expression of PAI-1 and enhanced green fluorescent protein were detected in coronary arteries, the aorta, and kidney of the mice.

Conclusions: Antiproliferative agents stimulate the expression of prothrombotic genes. PAI-1 expression may also play a role in the prevention of restenosis through an antimigratory mechanism. The effects of antiproliferatives on vascular gene expression deserve further scrutiny in view of the increasing utilization of drug-eluting stents.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Cell Proliferation / drug effects
  • Cells, Cultured
  • Coronary Restenosis / prevention & control
  • Coronary Thrombosis / etiology*
  • Coronary Thrombosis / genetics
  • Coronary Thrombosis / metabolism
  • Coronary Thrombosis / physiopathology*
  • Dose-Response Relationship, Drug
  • Drug Delivery Systems
  • Endothelium, Vascular / cytology
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism
  • Gene Expression Profiling
  • Green Fluorescent Proteins / metabolism
  • Humans
  • Mice
  • Mice, Transgenic
  • Muscle, Smooth, Vascular / cytology
  • Muscle, Smooth, Vascular / drug effects
  • Muscle, Smooth, Vascular / metabolism
  • Paclitaxel / administration & dosage
  • Paclitaxel / pharmacology*
  • Plasminogen Activator Inhibitor 1 / genetics
  • Plasminogen Activator Inhibitor 1 / metabolism*
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Risk Factors
  • Sirolimus / administration & dosage
  • Sirolimus / pharmacology*
  • Stents / adverse effects*
  • Tissue Plasminogen Activator / genetics
  • Tissue Plasminogen Activator / metabolism
  • Up-Regulation / drug effects
  • Up-Regulation / genetics

Substances

  • Antineoplastic Agents
  • Plasminogen Activator Inhibitor 1
  • RNA, Messenger
  • Green Fluorescent Proteins
  • Tissue Plasminogen Activator
  • Paclitaxel
  • Sirolimus